<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680953</url>
  </required_header>
  <id_info>
    <org_study_id>AMG162-A-J301</org_study_id>
    <nct_id>NCT00680953</nct_id>
  </id_info>
  <brief_title>Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis</brief_title>
  <acronym>DIRECT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of denosumab in the treatment of involutional
      (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral
      fracture(s)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo</measure>
    <time_frame>Baseline to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Non-vertebral Fractures</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The results are expressed as a percentage by Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1262</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate sodium hydrate</intervention_name>
    <description>Oral tablet once a week for 24 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Involutional (postmenopausal and senile) osteoporosis with prevalent fragility
             vertebral fractures

        Exclusion Criteria:

          -  Any underlying condition,(other than BMD) that might have resulted in abnormal bone
             metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiichi Sankyo</last_name>
    <role>Study Chair</role>
    <affiliation>R&amp;D Division, Daiichi Sankyo Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014 Jul;99(7):2599-607. doi: 10.1210/jc.2013-4175. Epub 2014 Mar 19.</citation>
    <PMID>24646104</PMID>
  </results_reference>
  <results_reference>
    <citation>Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18.</citation>
    <PMID>25403903</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>July 12, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2014</results_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Denosumab</title>
          <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
        </group>
        <group group_id="P3">
          <title>Alendronate</title>
          <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="511"/>
                <participants group_id="P3" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="414"/>
                <participants group_id="P2" count="416"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The demography information shows the number of participants included in the full analysis set (FAS) for efficacy analyses, which includes all randomized subjects except for those who did not have osteoporosis, did not receive the investigational product, or had no available efficacy data after the first dose of the investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>Denosumab</title>
          <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
        </group>
        <group group_id="B3">
          <title>Alendronate</title>
          <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="472"/>
            <count group_id="B2" value="480"/>
            <count group_id="B3" value="242"/>
            <count group_id="B4" value="1194"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" spread="7.36"/>
                    <measurement group_id="B2" value="69.0" spread="7.67"/>
                    <measurement group_id="B3" value="70.2" spread="7.31"/>
                    <measurement group_id="B4" value="69.6" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                    <measurement group_id="B2" value="456"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="1135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="472"/>
                    <measurement group_id="B2" value="480"/>
                    <measurement group_id="B3" value="242"/>
                    <measurement group_id="B4" value="1194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>the number of participants with vertebral fractures</title>
          <description>the number of participants with vertebral fractures</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="466"/>
                    <measurement group_id="B2" value="471"/>
                    <measurement group_id="B3" value="237"/>
                    <measurement group_id="B4" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo</title>
        <time_frame>Baseline to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
          </group>
          <group group_id="O3">
            <title>Alendronate</title>
            <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo</title>
          <units>Vertebral fractures</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.2" upper_limit="5.8"/>
                    <measurement group_id="O2" value="10.3" lower_limit="7.8" upper_limit="13.5"/>
                    <measurement group_id="O3" value="7.2" lower_limit="4.6" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.343</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.194</ci_lower_limit>
            <ci_upper_limit>0.606</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Non-vertebral Fractures</title>
        <description>The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
          </group>
          <group group_id="O3">
            <title>Alendronate</title>
            <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Non-vertebral Fractures</title>
          <description>The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.6" upper_limit="6.5"/>
                    <measurement group_id="O3" value="2.7" lower_limit="1.2" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9951</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.</title>
        <description>The results are expressed as a percentage by Kaplan-Meier estimate.</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
          </group>
          <group group_id="O3">
            <title>Alendronate</title>
            <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.</title>
          <description>The results are expressed as a percentage by Kaplan-Meier estimate.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1568</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 24 months</time_frame>
      <desc>The number of participants for which serious adverse reactions are reported are the ones included in the safety data analysis set. This data set includes all participants who received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Denosumab</title>
          <description>Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).</description>
        </group>
        <group group_id="E3">
          <title>Alendronate</title>
          <description>Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosal exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Paget's disease of the breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Haemangioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Mixed incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Vaginal relaxation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="475" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="481" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="242" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="475"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator shall not publish the results of the Study at any time without the prior written approval of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Takami</name_or_title>
      <organization>Daiichi Sankyo Co., Ltd.</organization>
      <phone>+81 3 5740 3445</phone>
      <email>takami.hideo.hs@daiichisankyo.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

